
To get the latest Beam stock quote, you can check the NASDAQ website, where Beam Suntory's stock is listed under the ticker symbol BEAM.
Beam Suntory is a leading global premium spirits company, with a market capitalization of over $30 billion.
The company's stock price can fluctuate significantly due to various market and economic factors, so it's essential to stay up-to-date with the latest quotes.
You can also check financial news websites, such as Bloomberg or Yahoo Finance, for the latest Beam stock quote and company data.
Broker Analysis
Broker analysis is a crucial aspect of investing in Beam Therapeutics Inc. The company has an average brokerage recommendation (ABR) of 1.75 on a scale of 1 to 5, indicating a strong buy.
The ABR is calculated based on the actual recommendations made by 16 brokerage firms, with 10 of them being strong buys, representing 62.5% of all recommendations.
The current ABR is comparable to the previous month's ABR of 1.82, based on 17 recommendations.
The number of recommendations in the current ABR is 16, and the average target price is $47.79.
Here is a breakdown of the analyst upgrades and downgrades:
The majority of analysts have a strong buy rating for Beam Therapeutics Inc., indicating a positive outlook for the company.
Company Data
Beam stock quote offers a lot to consider. Revenue for the company, as of the last reported quarter, stands at $349.643 million.
The company's earnings per share (EPS) for the same period is -$1.76. This is a significant indicator of the company's financial health.
Beam's stock has a beta of 2.19, which suggests that it's a relatively volatile investment. This can be a concern for risk-averse investors.
The company's 3-year Sharpe ratio is -0.2, and its 3-year Sortino ratio is -0.33. These ratios provide insights into the company's risk-adjusted performance.
Beam's volatility is quite high, at 93.04%. This means that the stock price can fluctuate significantly over short periods.
Here are some key metrics to keep in mind:
The company's 52-week range is $20.84 to $49.50. This indicates a significant price fluctuation over the past year.
Beam has 82.81 million shares outstanding. This can impact the stock's liquidity and price movement.
Global Data
Beam Global Registered Shs Estimates show a significant growth in revenue, with an average estimate of $71 USD for 2025, increasing to $100 USD in 2026, and reaching $121 USD in 2028.
The number of analysts making estimates for revenue has decreased, from 6 in the previous quarter to 4 in the next year. The average revenue estimate has increased from $14 USD in the previous quarter to $16 USD in the next quarter.
Here's a summary of the average revenue estimates:
Global Registered Shares in USD
The current price of Beam Global Registered Shs is $25.31, with a 0.20% increase after-market.
This price is based on the delayed data from NSDQ, which is updated in real-time.
The Zacks Rank system assigns a timeliness indicator to stocks, with a Strong Buy rating indicating a 24.30% annualized return.
The system also includes a VGM Score, which combines the weighted average of Value, Growth, and Momentum scores into one score.
A VGM Score of A indicates that the stock has a strong performance in all three areas.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank.
Here's a breakdown of the Zacks Rank system:
Analysts' opinions are also an important factor in determining the stock's performance. H.C. Wainwright & Co. has maintained a Buy rating for Beam Global Registered Shs since 05/22/24, with a price of $30.
Global Past Events
Global Past Events offer valuable insights into Beam Global's financial performance and milestones. The company has reported earnings for various quarters, with the lowest actual EPS being -1.990 USD at the Annual General Meeting in 2023.
Beam Global's financial reports have consistently shown negative EPS, indicating a decline in the company's performance. The Q4 2022 Earnings Release had an actual EPS of -0.770 USD.
The company's Annual General Meetings have also shown significant losses, with the lowest being -1.990 USD in 2023. This suggests that the company may be facing significant challenges.
Beam Global's earnings reports have been released on a regular basis, with the most recent one being the Q3 2024 Earnings Release, which had an actual EPS of 0.090 USD. This indicates a slight improvement in the company's performance compared to previous quarters.
Here's a summary of Beam Global's earnings reports:
The company's financial performance has been a topic of interest for investors, and these earnings reports provide valuable insights into its progress.
Frequently Asked Questions
Is BEAM a good stock to buy today?
Beam Therapeutics has a Moderate Buy rating with 74.81% upside potential, making it a potentially attractive investment opportunity. However, it's essential to do further research before making a buying decision.
What is the BEAM stock prediction for 2025?
BEAM stock is predicted to reach a price target of 49.20 USD, with estimates ranging from 23.00 USD to 80.00 USD. Analysts' predictions suggest a potential price increase for BEAM stock in the coming years.
What is the forecast for BEAM stock in 2024?
According to our latest forecast, BEAM's value is expected to increase by 0.41% and reach 0.0609 by December 31, 2024. However, the current market sentiment is bearish, with a Fear & Greed Index score indicating greed.
Featured Images: pexels.com